𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Adipocytokine levels in gastric cancer patients: resistin and visfatin as biomarkers of gastric cancer

✍ Scribed by Takako Eguchi Nakajima; Yasuhide Yamada; Tetsutaro Hamano; Koh Furuta; Takuji Gotoda; Hitoshi Katai; Ken Kato; Tetsuya Hamaguchi; Yasuhiro Shimada

Publisher
Springer Japan
Year
2009
Tongue
English
Weight
168 KB
Volume
44
Category
Article
ISSN
0944-1174

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Serum levels of vascular endothelial gro
Serum levels of vascular endothelial growth factor in gastric cancer patients
✍ Aydan Eroğlu πŸ“‚ Article πŸ“… 2011 πŸ› John Wiley and Sons 🌐 English βš– 38 KB πŸ‘ 1 views

It is known that vascular endothelial growth factor (VEGF) family is an important role in vasculogenesis and angiogenesis. Among the VEGF family members, VEGF-A plays an essential role in angiogenesis. However, the significance of serum levels of other VEGF members (VEGF-C and -D) has been reported

Increased incidence of undifferentiated
Increased incidence of undifferentiated type of gastric cancer with tumor progression in 912 patients with early gastric cancer and 1245 with advanced gastric cancer
✍ Yoichi Ikeda; Masaki Mori; Tatsuro Kamakura; Yukiaki Haraguchi; Motonori Saku; K πŸ“‚ Article πŸ“… 1994 πŸ› John Wiley and Sons 🌐 English βš– 525 KB

Background. There is little information concerning alteration in histologic differentiation with progression of gastric cancers. Methods. The authors analyzed data of 912 patients with early gastric cancer and 1245 with advanced gastric cancer. All patients underwent gastric resection. Special focu

mTOR as a therapeutic target in patients
mTOR as a therapeutic target in patients with gastric cancer
✍ Salah-Eddin Al-Batran; Michel Ducreux; Atsushi Ohtsu πŸ“‚ Article πŸ“… 2011 πŸ› John Wiley and Sons 🌐 French βš– 235 KB πŸ‘ 1 views

## Abstract The poor long‐term outcomes associated with current chemotherapy treatment of patients with advanced gastric cancer suggest a need for novel targeted agents that may confer a better survival benefit. Evidence of mammalian target of rapamycin (mTOR) activation has been demonstrated in pa